News | News By Subject | News by Disease News By Date | Search News

Cystic fibrosis News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Vertex Pharmaceuticals (MA) Grabs EU Recommendation For KALYDECO™ (Ivacaftor) In Eight Non-G551D Gating Mutations     6/27/2014
Vertex Pharmaceuticals (MA) Rockets As Cystic Fibrosis Combo Succeeds In Two Late Stage Trials     6/25/2014
Vertex Pharmaceuticals (MA) Trial Suggests Kalydeco May Work In More Cystic Fibrosis Patients     6/5/2014
Vertex Pharmaceuticals (MA) Reports Positive Ivacaftor Study Data, Plans To Initiate Larger Phase 3 Study     6/4/2014
One-Time Hepatitis C King Vertex Pharmaceuticals (MA) Shows Off Promising Phase 2 Cystic Fibrosis Data     5/5/2014
FDA Approves Vertex Pharmaceuticals (MA)'s KALYDECO™ (Ivacaftor) For Use In Eight Additional Mutations That Cause Cystic Fibrosis     2/24/2014
Vertex Pharmaceuticals (MA)'s Cystic Fibrosis Drug Ivacaftor Misses Goal In Late-Stage Study But Helps Some Adults     12/20/2013
AbbVie, Galapagos NV Ink $405 Million Cystic Fibrosis Pact     9/24/2013
Vertex Pharmaceuticals (MA) Shares Rocket as CF Drug Impresses in Phase 3 Study     8/1/2013
Insmed Incorporated Lung Antibiotic Passes Test But Falls Short of Investor Expectations     7/2/2013
These Mutated Cystic Fibrosis Cells are Worth Billions to Vertex Pharmaceuticals (MA)     6/17/2013
Vertex Pharmaceuticals Incorporated Booms on Cystic Fibrosis Combo Drug Study     4/23/2013
FDA Rejects Pharmaxis Ltd Drug Push Bid     3/19/2013
Vertex Pharmaceuticals Incorporated Readies Late-Stage Cystic Fibrosis Drug Studies     2/27/2013
Cystic Fibrosis Drug From Vertex Pharmaceuticals (MA) is Approved by Canadian Regulators     12/3/2012

Featured Stories
University of Pittsburgh-Led Study Suggests Cystic Fibrosis Is Two Diseases, One Doesn’t Affect Lungs     7/23/2014
Cystic Fibrosis And Diabetes Link Explained, Lund University Study     6/3/2014
New Drug Target Found for Cystic Fibrosis Lung Disease, BC Children's Hospital Study     11/8/2012
Sea Sponge Chemical Fixes Cystic Fibrosis Defect, McGill University Study     10/29/2012
Differences Seen in Lung Microbes of Cystic Fibrosis Patients, Stanford University Study     10/1/2012
Big Advance Against Cystic Fibrosis: Stem Cell Researchers Create Lung Surface Tissue in a Dish, Massachusetts General Hospital Study     4/6/2012
Student, 16, Invents New Drug Cocktail to Fight Cystic Fibrosis, Wins Canadian Biotech Challenge, National Research Council of Canada laboratories Reveals     5/12/2011
Cystic Fibrosis Patients May Benefit From Combination Therapy Which Provides Hope For Cure Of Dangerous Infections, McMaster University Study     4/25/2011
New Cystic Fibrosis Drug Improves Lung Function, University of Colorado Study     12/22/2010
Novel Drug Aids CF Kids' Lungs, University of Colorado Study     12/20/2010
Drug Corrects CF Genetic Defect, University of Colorado Reveals     11/18/2010
TOBI Reduces Mortality in Patients with Cystic Fibrosis, Pa Lung Infection, Children's Hospital Boston Study     10/22/2010
One Step Closer to a Drug Treatment for Cystic Fibrosis, University of Missouri Professor Says     10/12/2010
Growth Hormone May Benefit Lungs in CF, University of Connecticut/Hartford Hospital Evidence-Based Practice Center Study     10/7/2010
MP-376 Safe and Effective for Treatment of P. Aeruginosa in CF Patients, University of California, San Diego (UCSD) Study Finds     5/17/2010

More News
Cystic Fibrosis Foundation Applauds Successful Phase 3 Results Of Ivacaftor (Kalydeco™) And Lumacaftor (VX-809) Drug Combination For People With Two Copies Of F508del Mutation Of Cystic Fibrosis     6/24/2014
Vertex Pharmaceuticals (MA) (VRTX) Announces Presentation Of New KALYDECO™ (Ivacaftor) Data At European Cystic Fibrosis Society Conference     6/12/2014
Aradigm Corporation (ARDM) Receives $5 Million Milestone For Dosing Of The First Patient In Phase 3 Study Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis     6/3/2014
PTC Therapeutics, Inc. (PTCT) Release: Ataluren Phase 3 Trial Results In Nonsense Mutation Cystic Fibrosis Published In The Lancet Respiratory Medicine     5/16/2014
Rehmann’s 16th Annual Chef’s Fantasy Dinner and Auction” Benefitting the Cystic Fibrosis Foundation Held in Cleveland     5/5/2014
Vertex Pharmaceuticals (MA) (VRTX) Release: Addition Of VX-661 To KALYDECO® (Ivacaftor) Improves Lung Function In People With CF Who Are Heterozygous For The F508del And G551D Mutations In 28-Day Phase 2 Proof-Of-Concept Study     5/2/2014
FDA Grants Orphan Drug Designation For Bayer HealthCare (BAY)'s Investigational Ciprofloxacin DPI (Dry Powder For Inhalation) For Treatment Of Non-Cystic Fibrosis Bronchiectasis     4/23/2014
Xenetic Biosciences Announces Positive Phase 1 Clinical Data For Pulmoxen™ For Treatment Of Cystic Fibrosis     4/7/2014
Proteostasis Therapeutics, Inc. Announces Extension Of Funded Collaboration With Cystic Fibrosis Foundation Therapeutics, Inc. For Novel Therapies Targeting Most Common CF Mutation     3/4/2014
Galapagos NV (GLPG.BR) Receives EU2.9 Million IWT Grant For Cystic Fibrosis Research     1/13/2014
NovaBiotics Ltd Initiates Development Of Orphan Drug In Cystic Fibrosis     12/17/2013
Galapagos NV (GLPG.BR) Selects Pre-Clinical Candidate For Cystic Fibrosis     12/16/2013
Vertex Pharmaceuticals (MA) (VRTX) Announces Recent Progress and Upcoming Milestones in Research and Development Programs for Cystic Fibrosisv     10/17/2013
Galapagos NV (GLPG.BR) Presents Superior Potentiator Series for CF     10/17/2013
Cystic Fibrosis Foundation Therapeutics, Inc. Provides Savara $1.7 Million Award for Development of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients     10/17/2013

//-->